The anti-HER3 (ErbB3) therapeutic antibody 9F7-F11 induces HER3 ubiquitination and degradation in tumors through JNK1/2- dependent ITCH/AIP4 activation

Christophe Le Clorennec; Yassamine Lazrek; Olivier Dubreuil; Christel Larbouret; Marie-Alix Poul; Philippe Mondon; Gerry Melino; André Pèlegrin; Thierry Chardès

doi:10.18632/oncotarget.9455

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

The anti-HER3 (ErbB3) therapeutic antibody 9F7-F11 induces HER3 ubiquitination and degradation in tumors through JNK1/2- dependent ITCH/AIP4 activation

Christophe Le Clorennec, Yassamine Lazrek, Olivier Dubreuil, Christel Larbouret, Marie-Alix Poul, Philippe Mondon, Gerry Melino, André Pèlegrin and Thierry Chardès _

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2016; 7:37013-37029. https://doi.org/10.18632/oncotarget.9455

Metrics: PDF 2850 views | HTML 3391 views | ?

Abstract

Christophe Le Clorennec1,2,3,4, Yassamine Lazrek1,2,3,4,5,8, Olivier Dubreuil5,9, Christel Larbouret1,2,3,4, Marie-Alix Poul1,2,3,4, Philippe Mondon5,10, Gerry Melino6,7, André Pèlegrin1,2,3,4, Thierry Chardès1,2,3,4

1IRCM, Institut de Recherche en Cancérologie de Montpellier, Montpellier, F-34298, France

2INSERM, U1194 Montpellier, Montpellier, F-34298, France

3Université de Montpellier, Montpellier, F-34298, France

4ICM, Institut Régional du Cancer Montpellier, Montpellier, F-34298, France

5Millegen SA, Labège, F-31670, France

6Biochemistry Laboratory, Instituto Dermopatico Dell'Immacolata, Department of Experimental Medicine and Surgery, University of Rome “Tor Vergata,” 00133 Rome, Italy

7Toxicology Unit, Medical Research Council, Leicester University, Leicester LE1 9HN, United Kingdom

8Institut Pasteur de Guyane, BP 6010, 97306, Cayenne Cedex, France

9GamaMabs Pharma SA, Centre Pierre Potier, ONCOPOLE, BP 50624, France

10LFB Biotechnologies, 59000, Lille, France

Correspondence to:

Thierry Chardès, email: [email protected]

Keywords: cancer, HER3, ITCH/AIP4, antibody, treatment

Received: January 06, 2016 Accepted: April 16, 2016 Published: May 18, 2016

ABSTRACT

We characterized the mechanism of action of the neuregulin-non-competitive anti-HER3 therapeutic antibody 9F7-F11 that blocks the PI3K/AKT pathway, leading to cell cycle arrest and apoptosis in vitro and regression of pancreatic and breast cancer in vivo. We found that 9F7-F11 induces rapid HER3 down-regulation. Specifically, 9F7-F11-induced HER3 ubiquitination and degradation in pancreatic, breast and prostate cancer cell lines was driven mainly by the itchy E3 ubiquitin ligase (ITCH/AIP4). Overexpression of the ITCH/AIP4 inhibitor N4BP1 or small-interfering RNA-mediated knockdown of ITCH/AIP4 inhibited HER3 ubiquitination/degradation and PI3K/AKT signaling blockade induced by 9F7-F11. Moreover, 9F7-F11-mediated JNK1/2 phosphorylation led to ITCH/AIP4 activation and recruitment to HER3 for receptor ubiquitination and degradation. ITCH/AIP4 activity was activated by the deubiquitinases USP8 and USP9X, as demonstrated by RNA interference. Taken together, our results suggest that 9F7-F11-induced HER3 ubiquitination and degradation in cancer cells mainly occurs through JNK1/2-dependent ITCH/AIP4 activation.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 9455

Publication Alerts

Research Papers:

The anti-HER3 (ErbB3) therapeutic antibody 9F7-F11 induces HER3 ubiquitination and degradation in tumors through JNK1/2- dependent ITCH/AIP4 activation

Abstract